83 related articles for article (PubMed ID: 7733907)
21. Identification and characterization of a salivary adenosine deaminase from the sand fly Phlebotomus duboscqi, the vector of Leishmania major in sub-Saharan Africa.
Kato H; Jochim RC; Lawyer PG; Valenzuela JG
J Exp Biol; 2007 Mar; 210(Pt 5):733-40. PubMed ID: 17297134
[TBL] [Abstract][Full Text] [Related]
22. Activation of apoptosis in early mouse embryos by 2'-deoxyadenosine exposure.
Gao X; Blackburn MR; Knudsen TB
Teratology; 1994 Jan; 49(1):1-12. PubMed ID: 8171392
[TBL] [Abstract][Full Text] [Related]
23. Understanding the mode of inhibition and molecular interaction of taxifolin with human adenosine deaminase.
Rawat RS; Kumar S
J Biomol Struct Dyn; 2023 Feb; 41(2):377-385. PubMed ID: 34851227
[TBL] [Abstract][Full Text] [Related]
24. Induction of differentiation of human myeloid leukemia cells by 2'-deoxycoformycin in combination with 2'-deoxyadenosine.
Niitsu N; Umeda M; Honma Y
Biochem Biophys Res Commun; 1997 Sep; 238(1):100-6. PubMed ID: 9299460
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
Blatt J; Venner PM; Riccardi R; Cohen LF; Gangji D; Glazer RI; Poplack DG
J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome.
Law WR; Valli VE; Conlon BA
Crit Care Med; 2003 May; 31(5):1475-81. PubMed ID: 12771621
[TBL] [Abstract][Full Text] [Related]
27. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity.
Liu Y; Wolff KC; Jacobs BL; Samuel CE
Virology; 2001 Oct; 289(2):378-87. PubMed ID: 11689059
[TBL] [Abstract][Full Text] [Related]
28. Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.
Kutryb-Zajac B; Koszalka P; Mierzejewska P; Bulinska A; Zabielska MA; Brodzik K; Skrzypkowska A; Zelazek L; Pelikant-Malecka I; Slominska EM; Smolenski RT
J Cell Mol Med; 2018 Dec; 22(12):5939-5954. PubMed ID: 30291675
[TBL] [Abstract][Full Text] [Related]
29. Modulation of human cytidine deaminase by specific aminoacids involved in the intersubunit interactions.
Vincenzetti S; Quadrini B; Mariani P; De Sanctis G; Cammertoni N; Polzonetti V; Pucciarelli S; Natalini P; Vita A
Proteins; 2008 Jan; 70(1):144-56. PubMed ID: 17640070
[TBL] [Abstract][Full Text] [Related]
30. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
[TBL] [Abstract][Full Text] [Related]
31. Effects of 2'-deoxycoformycin on HL-60 cell differentiation, adenosine deaminase, and oligoadenylate synthetase.
Triozzi PL; Vicstein F
Am J Hematol; 1990 Apr; 33(4):274-6. PubMed ID: 2316512
[TBL] [Abstract][Full Text] [Related]
32. Pentostatin (2prime prime or minute-Deoxycoformycin): Clinical Pharmacology, Role In Cancer Chemotherapy, and Future Prospects.
Spiers AS
Am J Ther; 1995 Mar; 2(3):196-216. PubMed ID: 11847552
[TBL] [Abstract][Full Text] [Related]
33. Chromosome anomalies associated with amplification of the adenosine deaminase gene (ADA) in rat hepatoma cells.
Rowland P; Chiang J; Jargiello-Jarrett P; Hoffee PA
Cytogenet Cell Genet; 1986; 41(3):136-44. PubMed ID: 3485513
[TBL] [Abstract][Full Text] [Related]
34. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors.
Barankiewicz J; Danks AM; Abushanab E; Makings L; Wiemann T; Wallis RA; Pragnacharyulu PV; Fox A; Marangos PJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1230-8. PubMed ID: 9399998
[TBL] [Abstract][Full Text] [Related]
35. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
36. Modulation of adenosine release from rat spinal cord by adenosine deaminase and adenosine kinase inhibitors.
Golembiowska K; White TD; Sawynok J
Brain Res; 1995 Nov; 699(2):315-20. PubMed ID: 8616636
[TBL] [Abstract][Full Text] [Related]
37. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation.
Dong RP; Tachibana K; Hegen M; Munakata Y; Cho D; Schlossman SF; Morimoto C
J Immunol; 1997 Dec; 159(12):6070-6. PubMed ID: 9550406
[TBL] [Abstract][Full Text] [Related]
38. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
Terasaka T; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2005 Jul; 48(15):4750-3. PubMed ID: 16033254
[TBL] [Abstract][Full Text] [Related]
39. 2'-deoxycoformycin. A new anticancer agent.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
[TBL] [Abstract][Full Text] [Related]
40. Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV.
Richard E; Alam SM; Arredondo-Vega FX; Patel DD; Hershfield MS
J Biol Chem; 2002 May; 277(22):19720-6. PubMed ID: 11901152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
